Combination chemotherapy in the management of superior vena caval obstruction in small-cell anaplastic carcinoma of the lung.

Among 225 consecutive patients with small-cell anaplastic bronchogenic carcinoma, 26 (11.5%) had superior vena caval obstruction when the malignancy was diagnosed. Of these 26 patients, a consecutive series of 22 were treated initially with combination chemotherapy (cyclophosphamide, methotrexate and CCNU, in some cases combined with vincristine) alone, and in all these cases resolution of the syndrome was prompt within a median of 7 days. In no case were symptoms increased transiently by the treatment. No difference in response rate was observed between the histologic subtypes of small-cell anaplastic bronchogenic carcinoma according to the WHO classification. Combination chemotherapy alone is an effective treatment of superior vena caval obstruction in patients with small-cell anaplastic bronchogenic carcinoma.

[1]  F. Hirsch,et al.  Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. , 1978, Annals of internal medicine.

[2]  F. Hirsch,et al.  Peritoneoscopy in the staging of 190 patients with small‐cell anaplastic carcinoma of the lung with special reference to subtyping , 1978, Cancer.

[3]  H. Hansen,et al.  Cell proliferation and histologic classification of bronchogenic carcinoma. , 1977, Journal of the National Cancer Institute.

[4]  H. Hansen.  Management of lung cancer. , 1977, The Medical clinics of North America.

[5]  F. Hirsch,et al.  Bone‐marrow examination in the staging of small‐cell anaplastic carcinoma of the lung with special reference to subtyping: An evaluation of 203 consecutive patients , 1977, Cancer.

[6]  J. Minna,et al.  Advances in small cell bronchogenic carcinoma. , 1977, Cancer treatment reports.

[7]  D. Davenport,et al.  Response of superior vena cava syndrome to radiation therapy , 1976, Cancer.

[8]  R. Kane,et al.  Superior vena caval obstruction due to small-cell anaplastic lung carcinoma. Response to chemotherapy. , 1976, JAMA.

[9]  J. Lokich,et al.  Superior vena cava syndrome. Clinical management. , 1975, JAMA.

[10]  S. Levitt,et al.  Treatment of malignant superior vena caval obstruction. A randomized study , 1969, Cancer.

[11]  W. E. Miller,et al.  Radiographic abnormalities in carcinoma of the lung as related to histological cell type. , 1969, Thorax.

[12]  R. Rapp,et al.  The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. , 1968, Radiology.

[13]  E. Cliffton,et al.  Superior vena caval obstruction in carcinoma of lung. , 1965, New York state journal of medicine.

[14]  P. Rubin,et al.  SUPERIOR VENA CAVAL SYNDROME. SLOW LOW-DOSE VERSUS RAPID HIGH-DOSE SCHEDULES. , 1963, Radiology.

[15]  M. Schechter.  THE SUPERIOR VENA CAVA SYNDROME , 1954, The American journal of the medical sciences.

[16]  B. Roswit,et al.  The superior vena cava obstruction syndrome in bronchogenic carcinoma; pathologic physiology and therapeutic management. , 1953, Radiology.